Filter posts

Biotech Solutions for Zika

The Zika virus epidemic continues to rage on. Just today, the WHO advised people in Zika affected …

Strategic Venture Investing by Large Pharma: Is “Smart Money” Right for Your Company

The strategic venture arms of major biopharma companies like AbbVie, Amgen, Johnson & Johnson and …

Yoshinori Ohsumi, Ph.D., Receives 2016 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson presented cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology, …

Nailed It! Rock Star Panel

Today’s “Nailed It! Rock Star Panel,” sponsored by Johnson & Johnson Innovation/JLABS, featured three company …

Curative Therapies: Aligning Policy with Science to Ensure Patient Access

New hepatitis C medications with exceptionally high cure rates have significantly improved treatment, while also …

Facts Not Fiction: Digital Delivers Results for Biotech Companies

A panel of experts in the digital advertising space assembled Wednesday at the 2016 BIO International …

Antibiotic Development Incentives May Be Tricky to Implement

A recently proposed broad suite of antibiotic development incentives has received strong support from industry …

Janet Napolitano and Jim Greenwood Talk Innovation, Homeland Security, and Politics at #BIO2016 Fir...

Janet Napolitano, President of the University of California, emphasized the need for research at every …

Achieving Healthcare Sustainability: Can we Move from “Value” to “Predictability”?

Drug costs are one of largest healthcare concerns across the American political spectrum. But drug …

Shifting CAR-Ts Into a Higher Gear

After a three-year run-up of mounting excitement over CAR-T therapies comes crunch time. Over the …